Lyka Labs gets Indian Patent for diabetic neuropathic pain management gel Pregabalin

Mumbai: Lyka Labs Limited has announced that it has been granted an Indian Patent for its proprietary product, Pregabalin Gel 8 percent, with patent protection valid through 2043.

Pregabalin Gel 8%, a topical formulation designed for the effective management of diabetic neuropathic pain, received regulatory approval from the Central Drugs Standard Control Organization (CDSCO) in October 2024 for manufacturing and marketing in India.

Diabetic neuropathic pain, a common complication of diabetes, is nerve damage causing pain, numbness, and other sensations, often in the feet and legs, but can also affect other areas.

The product was officially launched in December 2024 by Torrent Pharmaceuticals, Intas Pharmaceuticals, and Zuventus Healthcare under a P2P (Product-to-Product) license from Lyka Labs.

This gel formulation offers localized delivery of pregabalin directly at the site of pain, potentially minimizing systemic exposure and related side effects commonly associated with oral formulations.

Read also: NPPA fixes ceiling price of Amphotericin B Emulsion Injection to treat Black Fungus

Lyka Labs has conducted clinical studies supporting the efficacy, safety, and patient convenience of Pregabalin Gel 8%, making it an alternative for millions suffering from chronic diabetic neuropathic conditions.

Lyka is a pharmaceutical company with strong capabilities in Sterile Preparations & Topical Preparations. From its R&D Centre in Mumbai, Lyka is currently working on development of a wide range of New Formulations and New Drug Delivery Systems in its focus areas of Lyophilized Injectables and Topical Preparations.

Read also: Lyka Labs Gets CDSCO Panel Nod To Manufacture, Market Atopic Dermatitis Drug